ABPO Abpro Holdings, Inc.

CIK 0001893219 49 ready 8-Ks latest February 20, 2026, 6:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 49

Latest filing February 20, 2026, 6:59 PM ET

Top materiality 0.85

Event mix other_material ×28 · regulatory ×11 · leadership ×5

Sentiment 9 pos · 14 neg · 26 neu

Executive change recent →

Recent 8-K filings for ABPO

Highest-materiality recent filing

Abpro receives Nasdaq delisting notice for failing minimum equity rule; trading to suspend Feb 23

February 20, 2026, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

Nasdaq Panel notified Abpro on Feb 18, 2026 that it failed to demonstrate compliance with Listing Rule 5550(b)(1) by Feb 16 deadline.
Trading of ABP common stock and ABPWW warrants will be suspended at the open on February 23, 2026.

Read filing →

February 20, 2026, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

Abpro receives Nasdaq delisting notice for failing minimum equity rule; trading to suspend Feb 23

Nasdaq Panel notified Abpro on Feb 18, 2026 that it failed to demonstrate compliance with Listing Rule 5550(b)(1) by Feb 16 deadline.
February 11, 2026, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 5.02 ◈ Listing & Compliance Notices ×2

Abpro receives Nasdaq delisting notices after board resignations; appoints two independent directors

Directors Eisenberg (Jan 28) and Lee (Jan 30) resigned from board and all committees.
February 3, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 5.02

Two directors of Abpro Holdings resign; board to fill vacancies

Anthony D. Eisenberg resigned from Board and all committees on Jan 28, 2026.
January 23, 2026, 6:59 PM ET other material materiality 0.35 neutral item 1.01 item 2.03 item 5.02 item 9.01 ◈ Debt Financings

Abpro Holdings gets $147K CEO loan for D&O insurance; director replaced

CEO Miles Suk lends $147,000 unsecured to fund D&O insurance premium; 9-month term, 3-month interest-free, then SOFR+2%.
January 6, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 7.01 item 9.01

Abpro and Celltrion announce FDA IND clearance for lead multispecific antibody ABP-102 / CT-P72

FDA cleared IND for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors.
December 15, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

Abpro submits IND to FDA for phase 1 trial of ABP-102/CT-P72 in HER2+ cancers

IND filed for ABP-102/CT-P72, a HER2×CD3 T cell engager targeting HER2-positive solid tumors.
December 9, 2025, 6:59 PM ET regulatory materiality 0.55 neutral item 7.01 item 9.01

Abpro Holdings granted Nasdaq extension to regain listing compliance

Received extension from Nasdaq Hearings Panel to achieve full compliance; deadline not specified.
November 4, 2025, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Abpro/Celltrion present preclinical data for CT-P72/ABP-102 at SITC 2025; poster in top 150

Poster selected as one of Top 150 abstracts out of >1,300 submissions at SITC 2025.
November 4, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

Abpro/Celltrion present top-ranked preclinical data for CT-P72/ABP-102 at SITC 2025

Poster selected as Top 150 abstract out of >1,300 submissions at SITC 2025.
November 3, 2025, 6:59 PM ET other materiality 0.60 neutral item 7.01 item 9.01

Abpro announces 1-for-30 reverse stock split effective Oct 31, 2025; trading begins Nov 3

Reverse stock split effective 5:01 p.m. ET Oct 31; stock trades split-adjusted from Nov 3 under ticker ABP.
October 22, 2025, 7:59 PM ET other material materiality 0.65 neutral item 5.03 item 9.01 ◈ Governance Changes

Abpro Holdings to effect 1-for-30 reverse stock split, reducing shares from 81.15M to ~2.7M

Reverse stock split ratio 1:30, effective Oct 31, 2025 at 5:01 p.m. EDT.
October 17, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices ×2

Abpro fails to regain compliance with Nasdaq MVPHS and MVLS; hearing Oct 30

Received Notice on Oct 14, 2025 that it did not regain MVPHS ($15M) or MVLS ($50M) compliance by Oct 7 deadline.
October 14, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07

Abpro Holdings shareholders approve 1-for-30 reverse stock split at 2025 annual meeting

Stockholders elected Ian McDonald as Class I director with 30,544,989 votes for, 8,122,953 withheld, and 10,863,999 broker non-votes.
October 3, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices

Abpro Holdings receives Nasdaq delisting notice for minimum bid price non-compliance

180-day compliance period ended Sep 29, 2025; bid price remained below $1.00.
October 2, 2025, 7:59 PM ET leadership materiality 0.55 negative item 5.02

Abpro Holdings furloughs CMO Robert Markelewicz; termination effective Nov 30, 2025

CMO Robert J. Markelewicz, Jr. furloughed effective Sept 30, 2025; will perform no duties until Nov 30.
July 24, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

Abpro enters consulting agreement with CEO Miles Suk's entity; $300K annual fee, 500K RSUs

BioCelsus International (wholly owned by Miles Suk) hired as consultant for CEO services; annual base fee $300,000 payable bi-weekly.
June 17, 2025, 7:59 PM ET other material materiality 0.30 neutral item 7.01

Abpro Holdings postpones 2025 annual meeting to later date

Board voted to postpone annual meeting originally scheduled for June 17, 2025.
April 28, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Abpro/Celltrion ABP-102/CT-P72 preclinical data at AACR 2025 shows potential best-in-class HER2 x CD3 T-cell engager

ABP-102/CT-P72 preclinical data presented orally at AACR 2025; co-developed with Celltrion via strategic partnership.
April 24, 2025, 7:59 PM ET debt materiality 0.35 neutral item 1.01 item 2.03 item 9.01

Abpro amends conversion price definition in Yorkville convertible note to fix scrivener's error

Amendment corrects 'Conversion Price' to lower of $11.50 fixed or 94% of lowest daily VWAP over 5 consecutive trading days.
April 16, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 3.01

Abpro Holdings receives Nasdaq deficiency notices: MVPHS below $15M, MVLS below $50M

Received two Nasdaq deficiency notices on April 10, 2025: MVPHS below $15M and MVLS below $50M.
April 15, 2025, 7:59 PM ET other material materiality 0.85 negative item 4.02

Abpro Holdings restates FY22, FY23, Q3 2024 due to $3.3M liability understatement

Audit committee concluded prior-period financials should no longer be relied upon.
April 8, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

Abpro Holdings receives Nasdaq minimum bid price deficiency notice; 180-day cure period.

Received Nasdaq notice on April 2, 2025, for failure to meet $1.00 minimum bid price requirement.
April 8, 2025, 7:59 PM ET other material materiality 0.15 positive item 5.07

Abpro shareholders approve >20% stock issuance to Yorkville under SEPA

Special meeting April 8, 2025; quorum of 50.7% of shares represented.
March 26, 2025, 7:59 PM ET other material materiality 0.55 neutral item 7.01 item 9.01

Abpro to present first preclinical data for bispecific HER2 x CD3 T-cell engager at AACR 2025

Oral presentation of ABP-102/CT-P72 at AACR 2025 in New Drugs on the Horizon session on April 27, 2025.
March 7, 2025, 6:59 PM ET leadership materiality 0.75 neutral item 5.02 ◈ executive_change ×2

Abpro terminates CEO Ian Chan, appoints Miles Suk as new CEO

Ian Chan terminated as CEO and principal executive officer, effective March 3, 2025.
March 6, 2025, 6:59 PM ET other material materiality 0.55 neutral item 3.03 item 9.01

Abpro Holdings adjusts warrant exercise price to $3.83 and redemption trigger to $5.99

Warrant exercise price reduced from $11.50 to $3.83 per share, effective March 5, 2025.
February 21, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Abpro provides pipeline update; Celltrion partnership for ABP-102 fully funded with up to $1.75B milestones

Celltrion funds all development of ABP-102 (HER2/CD3 T-cell engager) for breast/gastric cancer; Abpro retains 50% profit share.
December 12, 2024, 6:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Abpro celebrates business combination close; raises $10M and secures $50M equity facility

Business combination with ACAB closed Nov 13, 2024; Nasdaq bell ringing ceremony held Dec 12.
December 10, 2024, 6:59 PM ET other material materiality 0.60 negative item 4.01 item 9.01

Abpro Holdings dismisses Marcum as auditor; engages Wolf & Company; cites material weaknesses

Effective Dec 9, 2024, Abpro dismissed Marcum LLP and engaged Wolf & Company as independent auditor.
November 29, 2024, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change

Abpro CFO Shahraab Ahmad resigns effective Nov 22, 2024

Shahraab Ahmad notified the company of his resignation as CFO on Nov 21, 2024.
November 26, 2024, 6:59 PM ET M&A materiality 0.85 neutral item 1.01 item 2.01 item 9.01 item 5.02 item 3.02 item 2.03 item 3.03 item 5.01 item 5.03 item 5.06

Abpro Holdings completes de-SPAC merger with Abpro Corporation; stock begins trading Nov 14

Merger Consideration ~$500M: ~50M shares issued (39.1M to Abpro shareholders, 10.9M reserved for rollover RSUs/options).
November 13, 2024, 6:59 PM ET M&A materiality 0.70 neutral item 7.01 item 9.01

Abpro Holdings completes SPAC merger; to trade on Nasdaq under 'ABP' starting Nov. 14

Business combination between Abpro Corporation and Atlantic Coastal Acquisition Corp. II closed; approved by Atlantic Coastal stockholders on Nov. 7.
November 8, 2024, 6:59 PM ET other material materiality 0.60 neutral item 5.07 item 9.01

ACAB stockholders approve all proposals for Abpro business combination; 436K shares redeemed at ~$11.28

All 9 proposals passed with 7,587,598 votes for and 20,710 against (99.7% approval).
November 8, 2024, 6:59 PM ET other material materiality 0.75 negative item 1.01 item 8.01 item 9.01

ACAB enters forward purchase deal for up to 500K shares; 80.5% of public shares seek redemption

Forward Purchase Agreement with YA II PN for up to 500,000 recycled shares; prepayment from trust at ~$11.28/share.
November 8, 2024, 6:59 PM ET other material materiality 0.30 neutral item 8.01

Atlantic Coastal corrects redemption price to $11.34 per share in Abpro merger

Redemption price per Series A share corrected from $11.28 to $11.34 in connection with Abpro business combination.
November 6, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 9.01

ACAB enters non-redemption deal to reduce redemptions up to 124K shares before Abpro vote

Non-redemption agreement with Sandia Investment Management LP covering up to 124,352 shares.
November 4, 2024, 6:59 PM ET debt materiality 0.75 negative item 1.01 item 2.03 item 3.02 item 9.01

ACAB enters $50M equity line and $5M prepaid advance with Yorkville for post-merger financing

$5M prepaid advance via convertible notes with 8% original issue discount; $3M at merger close, $2M after registration effective and shareholder approval.
October 21, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 8.01

Atlantic Coastal gets Nasdaq delisting notice, extends SPAC deadline to Nov 19; S-4 effective for Abpro deal

Nasdaq delisting determination on Oct 16, 2024 for failure to meet market value of publicly held shares, round lot holders, and minimum publicly held shares requirements.
October 15, 2024, 7:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

ACAB files amended S-4, revised Abpro presentation; no new financial specifics

Filed amendment to Registration Statement on Form S-4 with SEC on Oct 9, 2024, for Abpro business combination.
September 20, 2024, 7:59 PM ET other material materiality 0.50 neutral item 5.03 item 5.07 item 9.01

Atlantic Coastal Acquisition Corp. II shareholders approve extension to Nov 19, 2024; 126,122 shares redeemed at ~$11.27

Charter amendment extends business combination deadline from Sep 19 to Oct 19, 2024, with optional further monthly extension to Nov 19, 2024.
September 4, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 7.01 item 9.01

ACAB amends Abpro merger to issue 600,601 shares to sponsor in lieu of $2M cash payment

ACAB will issue 600,601 shares of Series A common stock to its sponsor Atlantic Coastal Management II LLC, replacing $2,000,000 of Unpaid SPAC Expenses.
August 28, 2024, 7:59 PM ET other material materiality 0.70 positive item 1.01 item 3.02 item 7.01 item 9.01

ACAB enters PIPE agreements for $11.2M with Abpro Bio and Celltrion for business combination

Abpro Bio subscribes for 622,467 shares at $10/share ($6.2M total), with $4.2M portion via loan forgiveness.
August 19, 2024, 7:59 PM ET other material materiality 0.55 neutral item 8.01

SPAC extends business combination deadline by one month to Sep 19, 2024

Board extended deadline from August 19, 2024 to September 19, 2024 via resolution on Aug 16, 2024.
August 6, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

Atlantic Coastal Acquisition Corp. II receives Nasdaq delisting notice for failing minimum 400 holders

Received Nasdaq notice on July 31, 2024 for non-compliance with Listing Rule 5450(a) requiring minimum 400 holders of record.
July 19, 2024, 7:59 PM ET other material materiality 0.50 neutral item 8.01

Atlantic Coastal Acquisition Corp. II extends business combination deadline to August 19, 2024

Board extended the deadline from July 19, 2024 to August 19, 2024 (one month).
June 18, 2024, 7:59 PM ET other material materiality 0.40 neutral item 8.01

Atlantic Coastal Acquisition Corp. II extends business combination deadline to July 19, 2024

Board extended deadline from June 19, 2024 to July 19, 2024.
June 7, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 item 9.01

Nasdaq notifies Atlantic Coastal Acquisition Corp II of non-compliance for late Q1 2024 filing

Received Nasdaq notice on June 3, 2024 for failure to timely file Q1 2024 Form 10-Q (due May 15).
May 31, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01

ACAB enters expense advancement agreement with sponsor for up to $600k

Sponsor advances up to $600,000 aggregate, including $240,000 previously advanced, interest-free.
May 17, 2024, 7:59 PM ET other material materiality 0.35 neutral item 8.01

Atlantic Coastal Acquisition Corp. II extends business combination deadline to June 19, 2024

Board resolution extended the deadline from May 19, 2024 to June 19, 2024.

Executive changes

Appointed

Miles Suk

Chief Executive Officer

ABPO · Abpro Holdings, Inc.

Effective: 2025-03-07
Filed: March 7, 2025, 6:59 PM ET

By: /s/ Miles Suk Name: Miles Suk Title: Chief Executive Officer

Departed

Ian Chan

Chief Executive Officer

ABPO · Abpro Holdings, Inc.

Effective: 2025-03-03
Successor: Miles Suk
Filed: March 7, 2025, 6:59 PM ET

On March 7, 2025, Abpro Holdings, Inc. (the “Company”) announced that it had terminated Ian Chan as Chief Executive Officer and principal executive officer of the Company, effective as of March 3, 2025.

Departed

Shahraab Ahmad

Chief Financial Officer

ABPO · Abpro Holdings, Inc.

Effective: 2024-11-22
Filed: November 29, 2024, 6:59 PM ET

On November 21, 2024, Shahraab Ahmad notified Abpro Holdings, Inc., a Delaware corporation (the “Company”) of his resignation as the Company’s Chief Financial Officer, effective November 22, 2024.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

9 positive 14 negative 26 neutral

source · ABPO on sec.gov